From CAF subtypes to clinically relevant states: cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
- 1Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital
Abstract
Pancreatic ductal adenocarcinoma (PDAC) develops within a dense, poorly perfused tumor microenvironment (TME) in which cancer-associated fibroblasts (CAFs) are prominent cellular and structural components. Once viewed as a uniform population of activated matrix-producing cells, CAFs now include myofibroblastic, inflammatory, antigen-presenting and other populations identified by single-cell and spatial studies. These categories sharpen experimental resolution but do not form a stable hierarchy. CAF phenotypes overlap across spatial niches and disease stages, and they change under metabolic stress or treatment. We frame this heterogeneity as a set of context-dependent functional states. This review synthesizes evidence on fibroblast origins, canonical and recently reported states, and the signals that drive state transitions. It then examines CAF functions in extracellular matrix organization, tumor-cell plasticity and dissemination, metabolic support and immune regulation. Findings on tumor-restraining fibroblasts and protective collagen pools challenge indiscriminate stromal depletion. We also assess CAF states as prognostic and predictive biomarkers, their roles in treatment resistance and therapeutic strategies based on depletion, pathway blockade or stromal normalization. Failures of Hedgehog and hyaluronan-directed therapies show that target abundance alone cannot select patients. Clinical translation will require state definitions that integrate function, spatial context and treatment history, supported by reproducible markers, prospective validation and models that retain human stromal diversity.
Related
- Inferring clinically relevant molecular subtypes of pancreatic cancer from routine histopathology using deep learning
- Disulfidptosis-related genes stratify molecular subtypes and highlight MYH9 as a prognostic biomarker and candidate therapeutic target in pancreatic ductal adenocarcinoma
- Recent advances in cancer-associated fibroblasts in colorectal cancer: functional subtypes, spatiotemporal dynamics and therapeutic targets.
- Arrest-associated transcriptional programmes outweigh apoptosis-associated programmes in treatment-naive pancreatic ductal adenocarcinoma
- Keratin 17 Defines an Epithelial-Mesenchymal Transition-Associated Migratory Cell State in Pancreatic Ductal Adenocarcinoma
BibTeX
@article{hao2026from,
title = {{From CAF subtypes to clinically relevant states: cancer-associated fibroblasts in pancreatic ductal adenocarcinoma}},
author = {Yi Hao and Yi Wang and Qinyang Du and Gaopeng Li},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1971880},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1971880/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From CAF subtypes to clinically relevant states: cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
AU - Yi Hao
AU - Yi Wang
AU - Qinyang Du
AU - Gaopeng Li
PY - 2026
DA - 2026/10/06
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1971880
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1971880/full
AB - Pancreatic ductal adenocarcinoma (PDAC) develops within a dense, poorly perfused tumor microenvironment (TME) in which cancer-associated fibroblasts (CAFs) are prominent cellular and structural components. Once viewed as a uniform population of activated matrix-producing cells, CAFs now include myofibroblastic, inflammatory, antigen-presenting and other populations identified by single-cell and spatial studies. These categories sharpen experimental resolution but do not form a stable hierarchy. CAF phenotypes overlap across spatial niches and disease stages, and they change under metabolic stress or treatment. We frame this heterogeneity as a set of context-dependent functional states. This review synthesizes evidence on fibroblast origins, canonical and recently reported states, and the signals that drive state transitions. It then examines CAF functions in extracellular matrix organization, tumor-cell plasticity and dissemination, metabolic support and immune regulation. Findings on tumor-restraining fibroblasts and protective collagen pools challenge indiscriminate stromal depletion. We also assess CAF states as prognostic and predictive biomarkers, their roles in treatment resistance and therapeutic strategies based on depletion, pathway blockade or stromal normalization. Failures of Hedgehog and hyaluronan-directed therapies show that target abundance alone cannot select patients. Clinical translation will require state definitions that integrate function, spatial context and treatment history, supported by reproducible markers, prospective validation and models that retain human stromal diversity.
SN - 1664-3224
ER -